Ma Yijie, Walsh Michael J, Bernhardt Katharina, Ashbaugh Camille W, Trudeau Stephen J, Ashbaugh Isabelle Y, Jiang Sizun, Jiang Chang, Zhao Bo, Root David E, Doench John G, Gewurz Benjamin E
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Program in Virology, Harvard Medical School, Boston, MA 02115, USA.
Cell Host Microbe. 2017 May 10;21(5):580-591.e7. doi: 10.1016/j.chom.2017.04.005.
Epstein-Barr virus (EBV) causes endemic Burkitt lymphoma (BL) and immunosuppression-related lymphomas. These B cell malignancies arise by distinct transformation pathways and have divergent viral and host expression programs. To identify host dependency factors resulting from these EBV+, B cell-transformed cell states, we performed parallel genome-wide CRISPR/Cas9 loss-of-function screens in BL and lymphoblastoid cell lines (LCLs). These highlighted 57 BL and 87 LCL genes uniquely important for their growth and survival. LCL hits were enriched for EBV-induced genes, including viral super-enhancer targets. Our systematic approach uncovered key mechanisms by which EBV oncoproteins activate the PI3K/AKT pathway and evade tumor suppressor responses. LMP1-induced cFLIP was found to be critical for LCL defense against TNFα-mediated programmed cell death, whereas EBV-induced BATF/IRF4 were critical for BIM suppression and MYC induction in LCLs. Finally, EBV super-enhancer-targeted IRF2 protected LCLs against Blimp1-mediated tumor suppression. Our results identify viral transformation-driven synthetic lethal targets for therapeutic intervention.
爱泼斯坦-巴尔病毒(EBV)可引发地方性伯基特淋巴瘤(BL)以及与免疫抑制相关的淋巴瘤。这些B细胞恶性肿瘤通过不同的转化途径产生,并且具有不同的病毒和宿主表达程序。为了鉴定由这些EBV阳性、B细胞转化细胞状态所产生的宿主依赖性因子,我们在伯基特淋巴瘤和淋巴母细胞系(LCLs)中进行了平行的全基因组CRISPR/Cas9功能丧失筛选。这些筛选突出了57个对伯基特淋巴瘤生长和存活具有独特重要性的基因以及87个对淋巴母细胞系具有独特重要性的基因。淋巴母细胞系筛选命中的基因富含EBV诱导基因,包括病毒超级增强子靶点。我们的系统方法揭示了EBV癌蛋白激活PI3K/AKT途径并逃避肿瘤抑制反应的关键机制。发现LMP1诱导的cFLIP对于淋巴母细胞系抵御TNFα介导的程序性细胞死亡至关重要,而EBV诱导的BATF/IRF4对于淋巴母细胞系中BIM的抑制和MYC的诱导至关重要。最后,EBV超级增强子靶向的IRF2保护淋巴母细胞系免受Blimp1介导的肿瘤抑制。我们的结果鉴定出了可用于治疗干预的病毒转化驱动的合成致死靶点。